Filing Details
- Accession Number:
- 0000899243-21-038061
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-09-28 16:05:17
- Reporting Period:
- 2021-08-06
- Accepted Time:
- 2021-09-28 16:05:17
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1659352 | Codiak Biosciences Inc. | CDAK | Biological Products, (No Disgnostic Substances) (2836) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1867898 | Sriram Sathyanarayanan | C/O Codiak Biosciences, Inc. 35 Cambridgepark Drive, Suite 500 Cambridge MA 02140 | Chief Scientific Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2021-08-06 | 1,300 | $3.29 | 1,300 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-08-06 | 1,300 | $20.16 | 0 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2021-08-09 | 1,300 | $3.29 | 1,300 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-08-09 | 751 | $21.31 | 549 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-08-09 | 549 | $21.79 | 0 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Acquisiton | 2021-08-06 | 1,300 | $0.00 | 1,300 | $3.29 |
| Common Stock | Stock Option (Right to Buy) | Acquisiton | 2021-08-09 | 1,300 | $0.00 | 1,300 | $3.29 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 49,966 | 2027-07-24 | No | 4 | M | Direct | |
| 48,666 | 2027-07-24 | No | 4 | M | Direct |
Footnotes
- The transactions reported in this Form 4 were inadvertently reported late due to an administrative oversight related to communications of the transactions.
- The sales reported in this Form 4 were effected pursuant to a previously adopted Rule 10b5-1 trading plan.
- The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $20.03 to $20.26 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $20.72 to $21.71 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $21.72 to $21.91 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- The shares underlying this option are fully vested.
Billionaire Hedge Funds
